| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Clinical and Molecular Hepatology Search > Browse Articles > Search



Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
Shinya Sato, Kei Moriya, Masanori Furukawa, Soichiro Saikawa, Tadashi Namisaki, Mitsuteru Kitade, Hideto Kawaratani, Kosuke Kaji, Hiroaki Takaya, Naotaka Shimozato, Yasuhiko Sawada, Kenichiro Seki, Koh Kitagawa, Takemi Akahane, Akira Mitoro, Yasushi Okura, Junichi Yamao, Hitoshi Yoshiji
Clin Mol Hepatol.2019;25(1):65-73.   Published online February 25, 2019     
DOI: https://doi.org/10.3350/cmh.2018.0070
                              
Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
Soon Young Ko, Won Hyeok Choe
Clin Mol Hepatol.2018;24(4):351-357.   Published online March 16, 2018     
DOI: https://doi.org/10.3350/cmh.2017.0063
                              
Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
Jong Eun Yeon
Clin Mol Hepatol.2018;24(3):294-296.   Published online September 11, 2018     
DOI: https://doi.org/10.3350/cmh.2018.1009
                              
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol.2018;24(3):169-229.   Published online August 10, 2018     
DOI: https://doi.org/10.3350/cmh.2018.1004
                                 Cited By 1
Use of sofosbuvir in chronic kidney disease: Is it necessary?
Tae Seop Lim, Sang Hoon Ahn
Clin Mol Hepatol.2017;23(4):308-310.   Published online September 26, 2017     
DOI: https://doi.org/10.3350/cmh.2017.0109
                                 Cited By 2
Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea
Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
Clin Mol Hepatol.2015;21(4):358-364.   Published online December 24, 2015     
DOI: https://doi.org/10.3350/cmh.2015.21.4.358
                                 Cited By 7
Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
Suh Yoon Yang, Hyun Woong Lee, Youn Jae Lee, Sung Jae Park, Ki Young Yoo, Hyung Joon Kim
Clin Mol Hepatol.2015;21(2):125-130.   Published online June 26, 2015     
DOI: https://doi.org/10.3350/cmh.2015.21.2.125
                                 Cited By 2
No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients
Nae-Yun Heo, Young-Suk Lim, Woochang Lee, Minkyung Oh, Jiyun An, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Han Chu Lee, Yung Sang Lee, Dong Jin Suh
Clin Mol Hepatol.2014;20(2):177-184.   Published online June 30, 2014     
DOI: https://doi.org/10.3350/cmh.2014.20.2.177
                                 Cited By 4
The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients
Hee Jae Jung, Young Seok Kim, Sang Gyune Kim, Yun Nah Lee, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Boo Sung Kim
Clin Mol Hepatol.2014;20(1):38-46.   Published online March 26, 2014     
DOI: https://doi.org/10.3350/cmh.2014.20.1.38
                                 Cited By 22
Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
Seok Hoo Jeong, Young Kul Jung, Jae Won Yang, Sang Jin Park, Jong Woo Kim, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim
Clin Mol Hepatol.2012;18(4):360-367.   Published online December 21, 2012     
DOI: https://doi.org/10.3350/cmh.2012.18.4.360
                                 Cited By 10
A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
Byung Chul You, Young Seok Kim, Hun il Kim, Se Hun Kim, Seung Sik Park, Yu Ri Seo, Sang Gyune Kim, Se Whan Lee, Hong Soo Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kim
Clin Mol Hepatol.2012;18(3):272-278.   Published online September 25, 2012     
DOI: https://doi.org/10.3350/cmh.2012.18.3.272
                                 Cited By 1
Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients
Woo Jin Chung
Clin Mol Hepatol.2012;18(3):268-271.   Published online September 25, 2012     
DOI: https://doi.org/10.3350/cmh.2012.18.3.268
                                 Cited By 1
Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin
Sang Bun Choi, Youn Jae Lee, Jae Ik Lee, Young Jin Song, Byoung Jin Choi, Jong Han Kim, Eun Uk Jung, Sung Jae Park, Sang Heon Lee, Ji Hyun Kim, Jung Sik Choi, Sam Ryong Jee, Sang Yong Seol
Korean J Hepatol.2011;17(3):183-188.   Published online September 30, 2011     
DOI: https://doi.org/10.3350/kjhep.2011.17.3.183
                                 Cited By 3
Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C
Jae Hee Lim, Yun Nah Lee, Young Seok Kim, Sang Gyune Kim, Seung Won Jeong, Jae Young Jang, Hong Soo Kim, Sae Hwan Lee, Tae Kwann Park
Korean J Hepatol.2011;17(1):61-65.   Published online March 21, 2011     
DOI: https://doi.org/10.3350/kjhep.2011.17.1.61
                                 Cited By 8
New treatments for chronic hepatitis C
Jae Young Jang, Raymond T. Chung
Korean J Hepatol.2010;16(3):263-277.   Published online September 30, 2010     
DOI: https://doi.org/10.3350/kjhep.2010.16.3.263
                                 Cited By 14
Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection
Hong Ryeol Cheong, M.D., Hyun Young Woo, M.D., Jeong Heo, M.D., Ki Tae Yoon, M.D., Dong Uk Kim, M.D., Gwang Ha Kim, M.D., Dae Hwan Kang, M.D., Geun Am Song, M.D., Mong Cho, M.D.
Korean J Hepatol.2010;16(1):38-48.   Published online March 26, 2010     
DOI: https://doi.org/10.3350/kjhep.2010.16.1.38
         Cited By 9
Current status of Liver diseases in Korea: Hepatitis C
Young Suk Lim
Korean J Hepatol.2009;15(60):25-28.   Published online December 31, 2009     
DOI: https://doi.org/10.3350/kjhep.2009.15.S6.S25
         Cited By 17
A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis C
Mi Na Kim, M.D.1, Ki Tae Yoon, M.D.2,3, Jun Yong Park, M.D.1,3, Do Young Kim, M.D.1,3, Sang Hoon Ahn, M.D.1,3, Chae Yoon Chon, M.D.1,3, Kwang-Hyub Han, M.D.1,3
Korean J Hepatol.2009;15(4):496-503.   Published online December 31, 2009     
DOI: https://doi.org/10.3350/kjhep.2009.15.4.496
         Cited By 2
A case of sudden-onset hearing Loss in a patient treated with peginterferon α-2b and ribavirin for chronic hepatitis C
Min Ki Shin , Tae Hyo Kim , Kang Ju , Chang Yoon Ha , Hyun Ju Min , Woon Tae Jung , Ok Jae Lee
Korean J Hepatol.2009;15(3):370-374.   Published online September 30, 2009     
DOI: https://doi.org/10.3350/kjhep.2009.15.3.370
         Cited By 1
A Case of Bell`s Palsy Associated with Peginterferon Alfa-2a and Ribavirin Therapy for Chronic Hepatitis C Virus Infection
Moo Yeol Lee, M.D., Hoon Cho, M.D., Yeong Muk Kim, M.D., and Joon Sang Lee, M.D.
Korean J Hepatol.2006;12(3):444-448.   Published online January 1, 2000
      
Efficacy of Combination of Interferon α 2a , Ribavirin and UDCA in the Treatment of Chronic Hepatitis C
Dong Jin Suh , Neung Hwa Park , Young Hwa Chung , Young Sang Lee
Korean J Hepatol.1998;4(2):109-119.
      
Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C
Seong Kyun Na, Byung-Cheol Song
Received December 10, 2018     Accepted December 17, 2018     Published online January 21, 2019     
DOI: https://doi.org/10.3350/cmh.2018.0108    
[Epub ahead of print]
                              
Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?
Chung-Feng Huang, Ming-Lung Yu
Received December 18, 2018     Accepted December 25, 2018     Published online February 11, 2019     
DOI: https://doi.org/10.3350/cmh.2018.1014    
[Epub ahead of print]
                              
1 |
E-Submission
Email Alert
Author's Index
EndNote Style file download
The Korean Association for the Study of the Liver
The Liver Week 2019
SCImago Journal & Country Rank
PubMed Central
PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
DOAJ
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
ORCID
MeSH on Demand
COPE
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association for the Study of the Liver. All rights reserved.         
COUNTER
TODAY : 575
TOTAL : 113467